Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World use of clotting factor in iraqi haemophilia patients examined

NCT ID NCT06574984

Knowledge-focused Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study observed how 329 Iraqi male patients with haemophilia A used turoctocog alfa (a clotting factor) in their daily care. Researchers reviewed medical records to see how the drug was given and how many bleeding episodes occurred. The goal was to describe real-world treatment patterns, not to change how patients were treated.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
turoctocog alfa (a clotting factor VIII replacement therapy)
What this could lead to
If successful, this study could help doctors understand how turoctocog alfa is used in real-world settings and guide better management of haemophilia A.
What could go wrong
This is an observational study that only looks back at existing records, so it cannot prove cause and effect. Results may not apply to other populations or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

329 people

The number who actually took part.

Started

Nov 2024

Finished

Nov 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants received Turoctocog alfa intravenously.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Paediatric and adult male patients * On-demand and prophylactic patients with haemophilia A (any severity) * Only previously treated patients (previous FVIII replacement therapy) will be included in the study Exclusion Criteria: * Patients diagnosed with coagulation disorders other than haemophilia A such as Von Willebrand disease * Patients with documented presence of any FVIII inhibitor

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Congenital bleeding disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hemophilia A hemorrhagic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Congenital bleeding disorder Haemophilia A

Contacts and locations

Locations

  • Basrah Haemoplhilia centre

    Basra, 61001, Iraq

  • Hilla Haemophilia centre

    Hillah, 51001, Iraq

  • Karbala Haemophilia centre

    Karbala, 56001, Iraq

  • Kirkuk Centre for Cancer and Blood Disorders

    Kirkuk, 36001, Iraq

  • Najaf Haemophilia Centre

    Najaf, 54001, Iraq

  • National centre for Hamophilia

    Baghdad, 10001, Iraq

  • Novo Nordisk Investigational Site

    Baghdad, Iraq

More trials for these conditions

Other studies related to the condition(s) this trial covers.